Nanowear Announces FDA 510(k) Clearance for AI-enabled Continuous Blood Pressure Monitoring and Hypertension Diagnostic Management: SimpleSense-BP

Utilizing patented nanosensors fueling transformative AI, SimpleSense™, is the first wearable platform that enables physicians to securely and accurately offer patients full routine on cardiopulmonary examinations at-home, in healthcare facilities, and in clinical research.

NEW YORK, NY,/ January 4, 2024,/ BUSINESS WIRE/ – – Nanowear, a leader in healthcare-at-home remote diagnostics, announced that its nanotechnology-enabled wearable and software platform, SimpleSense^TM, has received FDA 510(k) clearance for a novel AI-enabled Software-as-a-Medical Device (SaMD). As the first non-invasive, cuffless, continuous blood pressure monitor, and diagnostic, SimpleSense-BP provides a transformational tool in clinical diagnostic management of hypertension and is additive to the wearable platform’s previously cleared cardiopulmonary diagnostics. — Read More…